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1. Introduction 
Therapy of glioblastoma has been very problematic with disappointing results using 
multiple therapeutic approaches. In general, glioblastomas are considered radioresistant 
tumors with different radiation modalities failing to control them in the clinic. However a 
comprehensive and detailed analysis of the radiosensitivity of glioblastoma cells has not 
been performed. We now present such an analysis in this chapter seeking a better definition 
of patterns of radiosensitivity in glioblastomas compared to other tumor cells. These data 
show that some glioblastomas have unusual responses to radiation that may render them 
more resistant to some forms of radiotherapy but also render them amenable to exploitation 
by other forms of radiotherapy. 
Multiple mechanisms have been proposed to be associated with radioresistance in human 
glioblastoma cells: Bao et al (1) have suggested increased DNA damage response. Karim et 
al (2) have proposed differential cyclo-oxygenase response in radioresistant glios. Brandani 
et al (3) have suggested HSP 70 elevation. Akuguka et al (4) have suggested increased rates 
in DNA double strand break rejoining association with micronuclei. Scmidberger et al (5) 
observed variation interferon-induced ǃ associates with increased radiosensitivity in four 
out of five glioblastomas. Yao et al (6) suggest variation in cell cycle arrest, modulation of 
the expression of cyclin-dependent kinase inhibitors, and autophagy. Streffer et al (7) 
showed BCL- family proteins modulate radiosensitivity in human malignant glioma cells. 
Kraus et al (8) showed aberrant p21 regulation in radioresistant primary glioblastoma 
multiforme cells bearing wild-type p53. Haas-Kogan (9) et al showed p53 function 
influences the effect of fractionated radiotherapy on glioblastoma tumors. Hsiao et al (10) 
showed functional expression of human p21(WAF1/CIP1) gene in rat glioma cells 
suppresses tumor growth in vivo and induces radiosensitivity. Yount et al (11) showed cell 
cycle synchrony unmasks the influence of p53 function on radiosensitivity of human 
glioblastoma cells. Britten et al (12) showed differential level of DSB repair fidelity effected 
by nuclear protein extracts derived from radiosensitive and radioresistant human tumour 
cells. Guichard et al (13) suggest potentially lethal damage repair as a possible determinant 
of human tumour radiosensitivity including glioblastoma. Kal et al (14) have suggested 
rhabdomyosarcomas, similar to glioblastomas are sensitive to low dose-rate irradiation.  
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These studies used multiple types of glioblastoma cells, but they did not define glioblastoma 
cells based on essential cellular response mechanisms. We will identify classes of 
glioblastoma cells that exhibit distinct mechanisms of radiosensitivity in vitro and in vivo. In 
general there is an overall correlation between radiosensitivity of tumor cells in vivo, 
radiosensitivity of xenograft tumors as measured in the laboratory and radiosensitivity of 
tumors in the clinic, although it is clear more studies between these three forms of 
radiosensitivity is needed. One purpose of this article is to provide such data for 
radioresistant glioblastoma 
Radiosensitivity as assayed by clonogenic inactivation is a precise and accurate endpoint 
measurable over a wide range of inactivation levels (circa 105) induced by a wide range of 
radiation doses (circa 103). Over this dynamic range, clonogenic inactivation can be 
measured with acceptable variation. Further, clonogenic inactivation is a dichotomous 
endpoint based on whether individual cells are either clonogenically inactivated or not. 
Mathematically, this enables the application of Poisson statistics to estimate the probability 
of inactivation for each increment of dose. Since 1956 when Puck and Marcus (15) published 
the first “survival curve” such patterns have been examined to discern underlying 
mechanisms that produce cellular inactivation. Although “hit-target” theory did not identify 
exact “hits” defined as patterns of ionizations or exact “targets” that once induced 
inactivates cell, these studies demonstrated a continuing concept that improves such 
estimates over specific dose-segments. The observation of a log-linear relationship over a 
specific dose-segment, e.g. logarithm of cells inactivated are a linear function of dose, 
indicates a constant rate of inactivation over that dose segment.  
From these early data a common pattern of inactivation was usually observed for tumor 
cells: a low rate of cell inactivation below circa 2 to 3 Gray (Gy) followed by increased rates 
of inactivation at higher doses. Further the patterns of inactivation at higher doses could be 
approximated as a log-linear response and the slope of such a dose-segment could be 
calculated as a Poisson probability of inactivation, usually expressed as the parameter Do, 
the dose needed to inactivate a single cell.  
Results from the huge empirical data base obtained in the clinic for the relative effect of 
different doses and protocols that induced both tumor regression and normal tissue toxicity, 
clearly demonstrated radiotherapy of some tumors was more successful when multiple 
doses below 3 Gy were used. Mathematical models were proposed to explain the rate of 
inactivation of tumors at lower doses circa 1 to 3 Gy and the most successful model was the 
“linear-quadratic (LQ) model” as proposed by Hendry ( 16) and by Fowler ( 17, 18). The LQ 
model was based on the concept that tumor cell inactivation was induced at a linear rate at 
lower doses (the alpha response) but reflected a quadratic component at higher doses 
determined by a coefficient beta times the square of the dose (the beta response). These 
efforts failed to identify specific targets or hits, which in retrospect, was partially due to the 
complex processes involved in cellular inactivation. However one basic observation from 
these analyses is useful: identification of a dose-segment over which inactivation is log-
linear, is still valid in identifying the rate of inactivation over such a dose-segment, 
represented by a single Poisson coefficient. 
The pioneering work of Joiner and his colleagues in identifying “low-dose hyper-
radiosensitivity” (19) demonstrated that at lower doses (< 0.5 Gy) there were additional 
changes in rates of clonogenic inactivation that could not be well explained by the linear-
quadratic model.  
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We have recently proposed that patterns of inactivation in tumor cells are expressed as two 
general responses, the alpha response and the omega (or quadratic) response, are in fact 
actually comprised of four distinct components induced sequentially at increasing doses 
(20). Three of these responses can be well fitted to a log-linear relationship and a Poisson 
coefficient could be calculated over each of these log-linear responses over distinct dose-
segments that represented the rate of inactivation. We will discuss these results 
subsequently but our data suggested that radiosensitivity of any cell line can be described as 
coefficients that describe four sequentially induced responses in each cell line. Some 
glioblastoma cells, not others, show specific values for these four responses.  
1.1 Concept of a “radiosensitivity phenotype” 
Our studies suggest that radiosensitivity of tumor cells cannot be expressed as a single 
parameter or histological type, but should be analyzed on the basis of descriptors of 
multiple responses that are specific to human tumor cell lines. We argue that the 
radiosensitivity phenotype of each cell line should be defined by a set of coefficients 
including: 1) relative rates of inactivation over  four distinct, sequentially-induced 
components that comprise radiosensitivity of each cell; 2) the general radiosensitivity group 
into which cell lines segregate non-randomly based on the values of exceptional coefficients; 
these groups associated with tumor cell genotype; 3) modulation of inactivation by reduced 
dose-rates; and 4) modulation of inactivation by the effect of ionization density of delivered 
radiations; and 5) modulation by in vivo mechanisms that are particular to genotype.  
In the next several paragraphs we identify those coefficients that together define the 
“radiosensitivity phenotype” of human tumor cells. One overall goal is to equate 
radiosensitivity phenotypes of tumor cells to genetic or epigenetic properties.  
1.2 Coefficients that describe four sequentially-induced responses in each human 
tumor cell  
We have measured clonogenic inactivation in multiple cell lines over different dose-
segments (20). These studies showed that response of tumor cells to radiation in vitro can be 
resolved into two general responses, termed the alpha response and omega response (or 
quadratic response) that represent the overall rate of inactivation over the dose-segment 
from 0 to circa 2 Gy (alpha response) and over doses greater than circa 3 Gy (omega 
response). These two general responses can be approximated by the linear and quadratic 
components of the linear-quadratic model. These two general responses vary not only 
between glioblastoma cell lines and other tumor types but also vary between different 
glioblastoma lines.  
Our data show these two general responses are actually comprised of four more specific 
responses induced sequentially in each cell line. Thus one goal of this chapter is to measure 
coefficients that describe these four responses in tumor cells and to suggest their relative 
importance in clinical radiotherapy.  
As stated above we have defined four sequentially-induced responses in ten tumor cell lines 
by increasing doses from 0.0 to 10.0 Gy. These responses are common to all tumor cells, 
induced at the same doses but vary in the rates of inactivation over these common dose-
segments. These four responses are:  
The hypersensitive (H) response is observed over the dose-segment from 0.0 to 0.10 Gy and 
is characterized by highest rates of clonogenic inactivation observed in tumor cells. This 
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response is related to low-dose radio-hypersensitivity as described by Joiner and his 
colleagues (19). In each cell line in which the H response is observed, it is expressed over the 
dose segment from 0.0 and 0.10 Gy with a very low threshold if any but ends at 0.10 Gy. The 
survival level at 0.10 Gy can be used to calculate the slope of the H response between 0.0 Gy 
and 0.10 Gy as ǂ (SF.1). The H response varies strongly in different types of tumor cells with 
some genotypes not expressing this response. Thus each cell line can be classified as to 
whether the H response is induced and the slope of the rate of inactivation. Interestingly, 
some glioblastoma cells express the H response at a high rate but are very radioresistant at 
higher doses.  
The resistant (R) response is observed over the dose-segment from 0.1 to 0.2 Gy and is 
characterized as increased resistance to clonogenic inactivation exhibited in each cell line 
that expresses the H response. The R response appears to be induced at circa 0.10 Gy in all 
cells and persists until it is terminated when the alpha* response is induced. The R response 
is coupled strongly to the H response. In our studies shown below the R response is not 
always expressed as a log-linear response across the dose-segment from 0.0 to 0.1 Gy and 
hence the change in rates of inactivation over the R response varies strongly with genotype. 
The expression of the H and R responses do not correlate with the expression of the alpha* 
and omega* responses.  
The alpha* (repair) response is induced at 0.20 Gy in all cells and once induced extends to 
all higher doses. The alpha* response is a protective response preventing excessive loss of 
irradiated somatic cells. The rate of inactivation over the alpha response is more resistant 
than rates evidenced over the H response and also more resistant than increased sensitivity 
observed subsequently when the omega* response is induced. The alpha* response is 
characterized by transiently suppressed apoptosis, induction of repair responses and 
perturbation of cell cycle progression. We refer to this induced response specifically as the 
alpha* (ǂ*) response and it is the only response determining inactivation between 0.2 and 2.0 
Gy. The slope of the alpha* response is a correlate of the general alpha response observed 
between 0.0 and circa 3 Gy measured either by the slope of inactivation estimated between 
0.0 and 2.0 Gy, ǂ (SF2) or by linear component of the linear-quadratic model ǂ (LQ). We will 
show examples of this relationship subsequently.  
The omega* (triage) response is induced at circa 3.0 Gy in all cells and extends to all higher 
doses. We refer to this induced response as the omega* (ω*) response and consider it a triage 
response that results is increased inactivation of damaged cells. It can be approximated 
mathematically by the quadratic response of the linear-quadratic model. The omega response 
is determined by linear regression of data above circa 3.0 Gy and its slope designated as omega 
(ω). The omega response is the combined effect of the omega* response induced as circa 3 Gy 
and an extension of the alpha* response. The omega* response is characterized by increased 
rates of clonogenic inactivation and chromosomal aberrations but decreased rates of 
tumorigenesis, carcinogenesis and mutation. Thus the increased inactivation of cells at doses 
above 3 Gy preferentially removes cells more likely to express mutation or cancer and thus can 
be considered a triage process that preferentially eliminates cells by detecting radiation-
induced properties and eliminating cells by post-repair apoptosis.  
1.3 Coefficients that describe the rates of inactivation over the alpha and omega 
responses segregate human tumor cells into only four statistically-valid cellular 
radiosensitivity groups 
In a broad survey of clonogenic inactivation in multiple tumor cells we observed that the 
rate of inactivation over the alpha response was the major determinant of overall cellular 
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radiosensitivity Williams et al (21, 22). The values of the coefficients that describe the alpha 
response derived over doses from 0 to circa 2.5 Gy segregated all cell lines non-randomly 
into four distinct, statistically-valid radiosensitivity groups. Each radiosensitivity group is 
inactivated over the alpha response at different rates and the statistical variation is 
significant. While the alpha response, that is in reality the combined effects to the H, R and 
alpha* responses, is related to the omega response in the four radiosensitivity groups, 
measurements of the general alpha response as will be shown subsequently, correlates with 
the alpha* response as measured using the linear-quadratic model. Thus the radiosensitivity 
groups listed below are dependent on the values of the alpha* response. Our work showed 
these four radiosensitivity groups segregate with specific genotypes, one of which was a 
group of some glioblastoma cells that as stated earlier express what we refer to as the “glio” 
response.  
All tumor types we examined segregated into only four cellular radiosensitivity groups:   
A VS (very sensitive) radiosensitivity group was comprised of only a single hypersensitive 
tumor line that was mutated in the ataxia telangiectasia mutated (ATM) gene. This cell line 
is hypersensitive to radiation on the basis of clonogenic inactivation, expression of 
apoptosis, cell cycle progression and susceptibility to chromosomal aberrations.  
An S (sensitive) radiosensitivity group was comprised of 17 cell lines all but one expressing 
wild type tumor protein 53 (wtTP53). The coefficients that describe the alpha response for 
these cell lines were intermediate between the VS cell line and other more resistant lines.  
An R (resistant) radiosensitivity group was comprised predominantly of  
cell lines that expressed a mutant form of TP53 although the exact form of mutation that 
renders cells more resistant has not been defined. R cells are intermediate in their 
radiosensitivity between S and R cells.  
A VR (very radioresistant) radiosensitivity group was identified that was comprised of 
only three human glioblastoma cells. For descriptive purposes, we will refer to the factor or 
gene that leads to this exceptional resistance as “glio”. This is in contradistinction to the S 
and R groups that contain tumor cells that derive from multiple histological types.  
1.4 Coefficients that describe radiosensitivity of tumor cells to low dose-rate 
irradiation 
We also defined rates of clonogenic inactivation of glioblastoma cell lines to low dose-rates 
(0.25 Gy per hour) compared to high dose rate (circa 50 Gy per hour) and again find 
significant differences in some radioresistant glioblastoma cell lines 21, 22. Importantly, 
these data suggest that some glioblastoma cell lines are distinctly different in their response 
to low dose-rate irradiation compared to their resistance to radiation delivered at higher 
doses. We will show analysis of these data subsequently below, but they do demonstrate 
that some glioblastoma cell lines that are very resistant as measured over the alpha* 
responses have a unique response to low dose-rate radiation that perhaps can be exploited 
in the clinic. Therefore a broad assessment of the radiosensitivity phenotype of a human 
tumor cell should include response to protracted irradiation.  
1.5 Coefficients that represent the susceptibility of radiosensitivity to differences in 
ionization-density  
While we will publish data elsewhere on the effects of dose-rate and ionization density, here 
we can make the general statement here that these data show the H and R responses are 
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generally not modified by either by dose-rate or ionization density. In contradistinction, the 
alpha* and omega* responses are highly susceptible to dose-rate and ionization density. 
1.6 Coefficients that represent the modulation of in vivo radiosensitivity by genotype 
and dose  
We demonstrated variation in the response of tumor xenografts to radiotherapy protocols 
based on genotype and dose-schedule. In these studies, Williams et al 21, we showed 
genotype of tumor cells influenced both in vitro radiosensitivity of tumor cells and also, by a 
different mechanism, influenced xenograft response in vivo. We attributed this effect, that 
was substantial in some cells, as an interaction between tumor genotype and the in vivo 
tumor microenvironment. Importantly one glioblastoma line that was in the VR cellular 
radiosensitivity group, expressed surprising sensitivity when irradiated as xenograft tumors 
in vivo.  
2. Methods and materials 
We have published in detail the exact protocols that we have used in these studies (21, 22, 
23, 24). 
2.1 Cell lines  
We study 3 radioresistant glioblastoma cell lines (U251, T98G and U87) two other lines 
classified as glioblastoma but are more sensitive (GL-13, JW-1T). We compare them in detail 
with two human colorectal tumor cell lines (DLD-1 and 19S184), both cells expressing 
mutTP53 but 19S186 has been abrogated in CDKN1A (p21) and this abrogation while not 
effecting in vitro radiosensitivity causes increased radiosensitivity in xenograft tumors 
(Waldemann, 24).  
2.2 Cell and culture techniques 
The basic media for colon tumor cell lines was McCoy 5A, supplemented with 10% FBS, 1% 
penicillin and streptomycin, 1% L-glutamine; Human glioma cell lines were cultured in 
DMEM/F12 with 10% FBS, 1% L-glutamine and 1% Penicillin and streptomycin. All cells 
were sub-cultured twice a week to maintain exponential growth. 
2.3 Cell survival assay 
Cells were plated ~18 hours before irradiation. Surviving colonies were determined 10-14 
days after irradiation depending on the cell line. Cells were stained with crystal violet and 
colonies counted (>50 cells/colony). Additional plates for each experiment were used as 
microcolony controls. Special care was taken in dispersing cell cultures to obtain single cell 
suspensions with high plating efficiencies.  
2.4 Irradiation 
Cells were irradiated in complete media in a Gammacell 40 (Nordion Ottawa ONT Canada) 
at approximately 0.7 Gy/min. Cells were plated 15 to 18 hours before irradiation with 
careful measurement of plating efficiency and multiplicity. After exposure, plates were 
incubated for 8-14 days depending on specific growth and colonies stained with crystal 
violet. Colonies with more than 50 cells were counted. For each cell line we performed 
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controls to account for possible proliferation during the period between plating and 
irradiation. This control consisted of plating 105 cells in separate plates when replicates of 
cells were plated for colony formation. When irradiation was performed on the plates for 
colony formation, the microcolony plates were stained and the number of cells per colony 
measured. The average number of cells per colony was below 1.20 cells per microcolony for 
all cell lines and did not vary significantly between cell lines. 
Low dose rate irradiation was carried out in a specially constructed Cs-137 irradiator with 
temperature control and the ability to irradiate cells with constant or exponentially-
decreasing dose-rates.  
2.5 Regrowth delay in xenograft tumors  
Tumors were established by subcutaneous injection of 5 million cells suspended in PBS into 
the upper thigh of nude mice. Each cohort included 6 to 13 tumors. Tumor growth rate was 
determined by measuring three orthogonal diameters of each tumor twice a week and the 
tumor volume estimated as Ǒ/6 [D1 x D2 x  D3], when individual tumor volumes reached 
~0.1-0.3 cm3, radiation treatment was initiated. Modal specific growth delay (mSGD) was 
measured for all cohorts in which a majority of tumors reached a volume four times the 
initial volume. Response was normalized to growth of unirradiated cells. We chose not to 
use the mean of specific regrowth delay patterns since a significant proportion of our 
cohorts included one or more tumors that did not regrow. Thus the mean became limited as 
a regrowth parameter. For cohorts for which some tumors did not regrow we estimated 
mSGD based on the regrowth pattern for the minority of tumors that did regrow. When we 
tested the sensitivity of modal to mean growth delay in selected cohorts in which all tumors 
regrew, the modal value always fell within one standard deviation of the mean. These 
methods share some characteristics of the methods described by Schwatchofer [25]. To 
provide an overview of the dichotomous response when some tumors regrow but some do 
not, we indicated such cohorts with an arrow showing this value, in terms of overall tumor 
response, was the common minimum response.  
3. Analyses 
3.1 Clonogenic inactivation of radioresistant glioblastoma cell lines 
In our previous studies (21, 22) we identified three glioblastoma cell lines (U251, T98G, U-
87) that were the most resistant of 39 cell lines examined as defined by comparison of 
clonogenic inactivation between circa 2 Gy and 10 Gy. These three radioresistant cell lines 
expressed two forms of TP53, with U251 and T98 expressing mutTP53 and U87 expressing 
wtTP53. For designation purposes we will refer to these three cell lines as expressing a VR 
radiosensitivity phenotype and expressing either a glio+mutTP53 genotype (U251 and T98G) 
or a glio+wtTP53 genotype. In figure 1 we compare clonogenic inactivation curves for these 
three VR (very radioresistant) glioblastoma cell lines compared to two colorectal cancer cell 
lines that fall into the R (radioresistant) radiosensitivity group wtTP53 (HCT116) and its 
subline abrogated in p21 (19S186) . 
The data in figure 1 show relative radiosensitivity between the five cell lines but it is 
important in our interpretation of these data to show them in the context of overall 
radiosensitivity of human tumor cell lines. In figure 1 there are clear differences between the 
three glioblastoma cell lines and the two more sensitive colorectal tumors. These differences 
vary with the dose-segment over which the data are presented.  
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Fig. 1. Radiosensitivity curves (2 to 10 Gy) for five cell lines: three radioresistant human 
glioblastoma cell lines, U251, T98G, U87, and two human colorectal tumor cell lines, HCT116 
and DLD-1. These data show standard survival measurements in the upper panel expressed as 
two general responses, the ǂ response from 0.0 to circa 3.0 Gy and the ω response for doses 
greater than circa 3 Gy. The lower two panels show three components that together constitute 
the alpha response: the H response, the R response and the ǂ* response.  
In the top panel the overall responses are shown between 0 and 10 Gy for the five cell lines 
and these responses can be analyzed by measuring the slope of inactivation between 0.0 Gy 
and 2.0 Gy and defined as the alpha response. The values for the alpha response calculated 
in this manner are significantly higher for VR cells than R cells but these differences are 
difficult to visualize at the scale used in this panel so the dose-response patterns are 
expanded in the lower panels.  
Similarly an omega response can be calculated for all five cell lines using linear regression 
of all data points above 4 Gy and the slopes of the five lines do not segregate between the 
two radiosensitivity groups, with two VR lines U251 and T98G showing a more resistant 
response than the third line U87. This dichotomy in response corresponds to the 
differences in these three lines in their expression of TP53. U251 and T98G express 
mutTP53 while U87 expresses wtTP53. These differences are shown more clearly 
subsequently. 
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In the bottom left panel the responses of all five cell lines are shown for their detailed 
responses over doses between 0.0 and 0.20 Gy. In this panel, the dashed lines are the slopes 
for each cell line defined by connecting 0.0 dose points to the points at 0.10 Gy, ǂ (SF.1), 
extended to illustrate the strong variation in slope for the H responses.  
All cell lines change in their rates of inactivation at 0.10 Gy that represents the induction of 
the R response. Note that the rates of inactivation over the R responses (0.1 to 0.2 Gy), varies 
between cell lines with U87 showing a marked increase compared to the other four lines. .  
In the lower right panel, the rates of inactivation over the alpha* responses are shown. The 
rates for the slopes of the alpha* response are calculated by the slopes between 0.20 and 2.0 
Gy indicated as ǂ (.2-2.). The slopes of the For this dose-segment, all three VR cell lines are 
more resistant than the two R lines.  
In a larger cohort of cells we have previously shown that the alpha responses of the three 
VR lines are distinctly more resistant (22). In our studies of multiple components (20) we 
showed that the alpha response is comprised of the “average” slope for the H, R and alpha* 
responses. This work also showed there is correlation between the alpha* response 
measured over the dose-segment from 0.2 Gy to 2.0 Gy an the general alpha response shown 
in the upper panel.  
3.2 Coefficients that define the alpha and omega responses segregate human tumor 
cells into four radiosensitivity groups 
In figure 2 we show a scatter diagram based on our data from Williams et al (21) expressed 
as values of the coefficients derived for the alpha and omega responses measured as shown 
in figure 1 and measured as the slope of the general alpha response and the omega response. 
This figure also specifically identifies the five cell lines that are the subject of our present 
analysis: U251, T98G, U87, DLD-1 and shows they are distinctly different in their 
radiosensitivity compared to the lines JW-1T and GL-13 purported also to be glioblastoma 
cells.  
There are important implications of these data. First the values of the alpha response and 
omega response segregate all cell lines into four statistically distinct radiosensitivity 
groups: VS, S, R and VR. The alpha response is the predominant determinate of 
radiosensitivity group. Note that the five cell lines that we study in this chapter are 
distributed in two clusters: U-251 and T98G are clustered in cell lines that express extreme 
resistance based on their alpha and omega responses. Three cell lines cluster in patterns 
with the lowest values for both alpha and omega responses, but three cell lines, DLD-1, 
19S186 and U-87 while showing resistance to lower doses (alpha response) have 
significantly larger values of the omega response are also determined as that are also 
resistant (alpha response) but show elevated values of their omega responses. Hence the 
three glioblastoma cells in the VR group share the smallest values for their alpha response 
but vary significantly in their omega responses. Two cell lines classified in the literature 
as glioblastoma GL-13 and JW-1T fall into distinctly different radiosensitivities 
segregating with the S radiosensitivity groups 
The omega response for U87 cells is distinctly higher, reflecting, we hypothesize, the role of 
wtTP53 in “glio” cells. We hypothesize that over the alpha response, “glio” confers 
radioresistance beyond that characterized by expression of mutTP53. At higher doses, 
wtTP53 modulates radiosensitivity as shown for U87 cells. The data in this figure show 
three distinct clusters of glioblastoma cell lines.  
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Fig. 2. Radiosensitivity of five glioblastoma cell lines in relationship to 34 other human 
tumor cell line data extracted from Williams et al 2008a. The ordinate is the coefficient that 
describes the slope of the alpha responses and the abscissa is the coefficient that describes 
the slope of omega responses as shown in figure 1. The diagonal lines are best fit estimates 
of regression and identify four distinct radiosensitivity groups (VS, S, R and VR). The “VR” 
(very resistant) group is comprised of only three radioresistant glioblastoma cell lines (U251, 
T98G, U87). In this figure we two cell lines that are also classified ad glioblastoma cell lines 
(JW-1T, GL-13) that do not segregate into the VR group. We also identify two R (resistant) 
cell lines DLD-1 and its subclone abrogated in p21, 19S186.  
3.3 Radiosensitivity of radioresistant glioblastoma cell lines and human colorectal 
tumor cells to low dose-rate irradiation 
We have previously measured the response of 27 human tumor lines to low dose-rate 
ionizing radiation (26) and in figure 3 we show the general responses of a VR cell line (U-
251) and a less resistant colorectal tumor cell line (DLD-1).  
These data show two important differences in these two cell lines. First the VR line is more 
resistant than the R line for both rates of radiation. Second, it is clear that within each line 
the differences between irradiation at HDR and LDR are markedly different for the two 
types of cells with the VR line showing a significant increase in inactivation by LDR.  
These differences in rates of clonal inactivation between LDR and HDR are shown in more 
detail in the data in figure 4. 
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Fig. 3. Comparison of clonogenic inactivation induced by acute high dose-rate HDR (50 
Gy/hr) and protracted irradiation LDR (0.25 Gy/hr). The dashed lines represent the 
extrapolation of the rate of inactivation at lower doses based on the slopes of inactivation by 
LDR and HDR.  
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Fig. 4. Clonogenic survival patterns for two glioblastoma cell lines (U251, U87) and two 
colorectal tumor cell lines (HCT116 and DLD-1) irradiated with either HDR (50 Gy/hr) and 
LDR (0.25 Gy/hr). Data for each cell line are shown as two panels, the upper panel shows 
surviving fraction, lower panels show the rate of cell killing calculated as logs killed per Gy 
between sequential time points. The slopes of cell killing curves are represented by: ǂ(HDR) 
which is measured from the slope of the line from 0.0 to surviving fraction at 2.0 Gy HDR; ǂ 
(LDR) which is the slope of the line from 0.0 to 6.0 Gy LDR; the slope of the cell killing curve 
at doses greater than 4 Gy HDR determined by linear regression, ω (HDR); and the slope of 
cell killing at LDR doses greater than 6 Gy, ω (LDR). In the lower panels, the rate of cell 
killing by HDR is indicated by dotted, dashed lines.  
These data show that both glioblastoma cell lines are inactivated by low dose-irradiation at 
approximately the same rates similar to rates for both colorectal tumor cells, showing a clear 
increase in rate that surpasses the levels of high dose-rate inactivation (omega response) of 
both cell types. This rate of LDR inactivation surpasses the rate of inactivation for the omega 
response for U-251 but the elevated level of U-87 cells for the omega response is not 
achieved.  
These data suggest strongly that for radioresistant glioblastoma cells, the rate of inactivation 
by LDR irradiation can surpass the rate of inactivation for by multiple fractions that induce 
inactivation along the alpha response.  
This in turn suggests using LDR radiotherapy for glioblastoma tumors and we synthesize 
our data to demonstrate the relative effect of different dose rates for induction of clonogenic 
inactivation. These data are shown in figure 5.   
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Fig. 5. Changes in the rate of cell killing expressed as Log10 of cells killed per Gy as a 
function of time of protracted irradiation in U251 cells irradiated with 4 different constant 
dose-rates and one that begins at 0.49 Gy/hr and decays with a half life of 2.7 days. The 
horizontal dotted and dashed lines represent the rate of cell killing for HDR irradiation at 
lower doses (alpha) and higher doses (omega).  
These data show that increasing dose-rate increases the rate at which cells are inactivated 
until dose-rates reach approximately 0.12 Gy/hr when there is a relatively common 
response for higher dose-rates including our chosen LDR of 0.25 Gy/hr. The diagonal 
dashed lines in figure 5 are a general indication of the relative effects of dose-rate compared 
to the relative effects of duration of exposure (time). In our previous studies of LDR 
irradiation in multiple tumor cells we show that all cell lines change in their rates of 
inactivation at circa 20 to 24 hours, so duration of exposure and dose-rate are both factors in 
achieving changes in clonogenic inactivation. 
The data in figure 5 suggests that dose rates in the range of 0.25 to 0.49 Gy/hr increase 
tumor cell inactivation to rates that exceed that can be achieved by the alpha response 
induced by HDR irradiation. Thus, these patterns of inactivation show that glioblastoma 
cells while resistant to radiotherapeutic protocols that use multiple fractions below circa 3 
Gy, are more sensitive to protracted irradiation.  
Together with J.A. Williams, we have shown that combining irradiation delivered by an 
implanted radioactive seed with concomitant external beam fractionated radiotherapy 
produces significant increases in tumor response (Williams JA et al 1998). This study 
established the feasibility of combining brachytherapy and external beam radiotherapy to 
achieve good responses in radioresistant glioblastoma cells.  
3.4 Radiosensitivity of xenograft tumors comprised of two R cells compared to a 
radioresistant glioblastoma cell line  
The response of xenograft tumors that differ in their susceptibility to clonogenic inactivation 
in vitro also vary in their radiosensitivity to different radiotherapy protocols delivered in 
vivo.  
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We performed a large set of experiments that compared the response of eight different cells 
that vary in their in vitro radiosensitivity to different radiotherapy protocols in vivo 
(Williams et al 2010). These studies showed a strong correlation between the total cells killed 
in vitro with tumor response but also showed a new in vivo effect that resulted from an in 
vivo interaction between tumor cell genotype and tumor microenvironment. Response of 
xenograft tumors comprised of two R cell lines, DLD-1 and 19S186 cells are compared to the 
very resistant VR line U-251 in figure 6.  
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Fig. 6. Growth of cohorts of xenograft tumors comprised of DLD-1, 19S186 and U-251 
glioblastoma cells to four radiation protocols: 8 x 2 Gy, 2 x 5Gy, 1 x 7.5 Gy and 1 x 15 Gy. 
The ordinate in these figures represent the median log V/Vo. Tumors that were irradiated at 
approximately 0.2 gm and their volumes measured with time. Tumor size is expressed as 
median tumor volume as a function of days after irradiation.  
The data in figure 6 show an increase in tumor radiosensitivity compared to their in vitro 
radiosensitivity for glioblastoma cells.  
In detailed analysis of 40 experiments similar to those shown in figure 6, we showed tumor 
response could be resolved into two independent sensitivity factors: τ and ρ (23 ). The factor 
τ is related to total cells inactivated in vitro by each protocol and is dependent on genotype, 
fraction-size ant total dose. The factor ǒ is dependent on genotype, fraction-size and total 
dose, but is independent of τ. We showed that for each protocol and genotype tumor 
response was dependent on the product of τ and ǒ. 
The relationship between τ and ǒ is a useful comparison for radiosensitivity of xenograft 
tumors induced in tumor that vary in genotype and treated with different protocols. These 
coefficients are shown in figure 7 for DLD-1, 19S186 and U-251 cells.  
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Fig. 7. Relative in vitro radiosensitivity (τ) and in vivo radiosensitivity (ǒ) for two R cells, 
DLD-1 and 19S186 and a radioresistant glioblastoma cells U-251. Each data point represents 
tumor response of each cell line to one of four protocols. Data point representing the two 
fractionated protocols, 8 x 2 and 2 x 5,  are connected by a dashed lines and these responses 
are very similar for U-251 cells but are markedly different for the two R cell lines. The 
response for each cell line to a single dose of 7.5 Gy is connected by an arrow to response of 
the same tumor to a single dose of 15 Gy. These increased responses are significant beyond 
the differences observed in fractionated protocols. 
These data show important differences between the response of glioblastoma cell line and 
the two R cell lines. First, the contribution of in vivo radiosensitivity represented by ǒ to 
responses of the glioblastoma line is remarkably greater than the contribution of this 
sensitivity in R cells. In contradistinction, the values for the in vitro component of tumor 
radiosensitivity in vitro, τ, are diminished, this diminution similar to differences predicted 
by in vitro clonogenic inactivation. The effects shown in this figure are large up to a factor of 
50 to 100 in doses to induce equivalent regression or in doses needed to induce the same 
levels of regression.  
4. Conclusions  
4.1 Glioblastoma cells express a diverse radiosensitivity phenotype 
Our studies show that cell lines designated as “glioblastoma” in the literature are diverse in 
their radiosensitivity phenotypes.  
4.1.1 Some glioblastoma cell lines express a low rate of inactivation over the alpha* 
response 
In our studies these reduced rates underlay the observation that such cell lines are refractory 
to doses over the alpha response. Specifically we hypothesized that these cell lines, express 
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“glio”, an unidentified genetic or epigenetic factor, that renders such glioblastoma cells 
resistant to radiation delivered at doses below circa 3 Gy. This in turn suggests that tumors 
comprised of cells that express glio and fall into the VR radiosensitivity group will be 
refractory to radiotherapy that is based on multi-fraction of cells when fractions are below 
3.0 Gy. 
4.1.2 The alpha* response can be uncoupled from the omega response in VR resistant 
glioblastoma cells  
Our data show that while two radioresistant glioblastoma cell lines (U-251 and T98G) show 
resistance to inactivation at higher doses (omega response), one cell line (U-87) shows a 
more sensitive response. We hypothesize that this difference is associated with expression of 
TP53 in these cell lines, U-251and T98G express mutTP53 while U-87 expresses wtTP53. 
These differences are consistent with the ration between alpha and omega responses for 
cells that express mutTP53 versus wtTP53 as shown in figure 3 and are consistent with all 
VR cells expressing glio but susceptible to the effect of expression of TP53. 
4.1.3 Glioblastoma cells that express VR radiosensitivity after high dose-rate 
irradiation show an unpredicted sensitivity to low dose-rate irradiation for dose-rates 
circa 0.25 to 0.49 Gy/hr 
 Glioblastoma cell lines that show VR radiosensitivity secondary to their expression of glio 
when irradiated with high dose-rate show a relatively more sensitive response to low dose-
rate irradiation for dose-rates circa 0.25 to 0.49 Gy/hr. The data in figures 5 and 6 show that 
two VR lines, U-87 and U-251 show rates of inactivation when irradiated with lower dose-
rates that are more sensitive than the rates of inactivation over the alpha response igh dose-
rate irradiation, response to LDR irradiation by exhibiting a more sensitive response show 
elevated rates of inactivation.  
4.1.4 Protocols that combine brachytherapy with external beam are highly effective in 
treating xenograft tumors of glioblastoma cells  
Led by JA Williams (27) we have shown that xenograft tumors of U-251 glioblastoma cells 
are highly susceptible to the combined effects of brachytherapy using single seeds and 
external beam radiotherapy. These data shows that xenograft tumors that are resistant to 
lower fractions (2 and 5 Gy) and protracted radiation from implanted radioactive seeds are 
highly response to their response to protocols that combine these two modalities.  
5.1 Implications for new approaches to radiotherapy of glioblastoma cell lines based 
on their radiosensitivity phenotype 
 Our data suggest relationships between the radiosensitivity phenotypes of glioblastoma 
cells and their predicted response to different radiotherapy protocols.  
5.1.1 Cells that express the VR radiosensitivity phenotype will be refractory to 
protocols that use multiple fractions of doses lower than 3.0 Gy 
 Cells the express the VR radiosensitivity phenotype have low rates of inactivation by doses 
below 3 Gy (alpha response) and should not respond well to protocols that use smaller 
fraction sizes.  
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5.1.2 VR glioblastoma cells that express wtTP53 should be more responsive to 
protocols that use higher doses per fraction (> 3 Gy)  
The data in figures 1, 2 and 3 show that U87 cells that express the VR phenotype but also 
express wtTP53 are more sensitive to doses that elicit the omega response (> 3 Gy) than the 
other two VR cells. This would suggest that tumors comprised of this form of VR cells 
would show significantly more inactivation than VR cells that express mut TP53 when doses 
are used that elicit the omega* response.  
5.1.3 The VR cell line U 251 shows increased radiosensitivity of its xenograft tumors 
irradiated in vivo compared to other cell types 
This increased response in vivo is observed for all protocols for glioblastoma cell line U-251 
but is significantly elevated for protocols that use large fractions of 7.5 Gy and 15.0 Gy. This 
in turn suggests that some forms of VR glioblastoma cells will respond to hypofractionation 
with fractions circa 7.5 to 15.0 Gy.  
6. Our observations suggest certain studies are needed to design protocols 
to exploit the VR radiosensitivity phenotype observed in some glioblastoma 
cell lines 
Our research suggests several studies would improve selection of radiotherapy protocols 
that could improve therapeutic results from specific protocols.  
6.1 Better markers are needed to define the VR radiosensitivity phenotype from tumor 
biopsies 
Our studies overall suggest there is no single protocol that would be predicted to provide 
maximum improvement in tumor radiotherapy for all variations in the radiosensitivity 
phenotypes that we  have observed in cells believed to be “glioblastoma” cells. 
6.2 The data base on the VR radiosensitivity phenotype need to be extended to 
include more cells presumed to be glioblastoma cells 
It seems clear from our work and that of others that a larger number of presumed 
glioblastoma cells need to be examined for their radiosensitivity phenotype including 
response to high dose-rate, to low dose-rate and their response as xenograft tumors to 
selected protocols.  
6.3 The mechanisms that underlay increased in vivo response of tumors comprised of 
U-251 glioblastoma cells needs to be extended to other glioblastoma cells 
Our data show this is a significant increase in radiosensitivity and the mechanisms that 
underlay it need to be studied in detail. The data we have presented offers a useful range of 
responses in different genotypes to study the role of genotype, fraction-size and total dose 
on this effect. 
7. Overall conclusions  
Radiosensitivity phenotypes of tumor cells are comprised of distinct, multiple responses to 
radiation. Glioblastoma cells exhibit responses that are both sensitive and resistant 
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compared to other tumor cells. Specific protocols can be designed to exploit these 
differences in radiosensitivity.  
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